Please assess the completion status of the following clinical trial:

Trial Title: Probiotics and the Prevention of Traveler's Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged 18 or over. Upper age limit set by subject's ability to participate in the study;~2. Subject must give written informed consent;~3. Plan to travel to a geographic area with high risk of TD with a travel duration between 12 and 14 days;~4. Subjects must be willing to refrain from using anti-diarrheal medications or antibiotics during the study period, unless they become clinically indicated in which case a rescue regimen can be administered;~5. Subjects willing to refrain from eating yoghurt and taking other probiotics during the study;~6. Female subjects of child-bearing potential must agree to use adequate birth control during the study period. This will be defined as hormonal contraception or a double barrier-method.~Exclusion Criteria:~1. Subjects who have been previously treated with PROTECFLOR® or who have participated in previous Lallemand-sponsored studies;~2. Subjects who have been born in a developing country.~3. Subjects with a history of substance or alcohol abuse or any other psychological condition that may, in the investigator's opinion, adversely affect their co-operation with the study;~4. Subjects who receive a cholera vaccine~5. Subjects with chronic diarrhea;~6. Subjects with chronic disease such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) or ulcerative colitis (UC) ;~7. Subjects with gastrointestinal (GI) surgery during the last 3 months;~8. Subjects who took systemic antibiotic 15 days or less prior to the study;~9. Subjects with immunodeficiency's or immune suppression;~10. Subjects being treated for cancer with radiotherapy and/or chemotherapy;~11. Subjects with organ transplants;~12. Subjects treated with immunosuppressant drugs;~13. Subjects receiving another probiotic preparations or having received probiotic preparations within the last 15 days;~14. Subjects with tube feeding, ileostomy and colostomy;~15. Subjects diagnosed Clostridium difficile colitis within the last 3 months;~16. Women who are pregnant, or who will not consent to using adequate birth control during the study period;~17. Women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Protecflor (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).